Mostrar el registro sencillo del ítem
Aspectos biomédicos de las fosfolipasas A2 en la especie humana
dc.contributor.author | García Morán, Grégory Alfonso | spa |
dc.contributor.author | Gaitán, Álvaro Andrés | spa |
dc.contributor.author | García Cardona, Ananías | spa |
dc.contributor.author | Clavijo Grimaldi, Dianney | spa |
dc.contributor.author | Ramón Mejía, Ómar | spa |
dc.contributor.author | Cobos, Claudia | spa |
dc.contributor.author | Casadiego, Ciro Alfonso | spa |
dc.date.accessioned | 2020-10-27T14:20:59Z | |
dc.date.available | 2020-10-27T14:20:59Z | |
dc.date.issued | 2008-04-11 | |
dc.identifier.issn | 2382-4603 | |
dc.identifier.issn | 0123-7047 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12749/10321 | |
dc.description.abstract | Las fosfolipasas son un grupo ubicuo y diverso de enzimas, descritas desde 1967, que inducen cambios en la composición membranal, activan la cascada inflamatoria y alteran las vías de señalización celular. Las fosfolipasas A2(PLA2) son enzimas responsables por la movilización de ácidos grasos, incluyendo el ácido araquidónico(AA), a partir de los fosfolípidos. Estas enzimas son clasificadas en las PLA2 citosólicas de alto peso molecular y las PLA2 secretorias de bajo peso molecular. El metabolismo del ácido araquidónico puede seguir su metabolismo a múltiples e interrelacionadas rutas, promoviendo la generación y la liberación de una amplia variedad de sustancias biológicamente activas. Las células inflamatorias son capaces de liberar ácido araquidónico, el cual puede ser metabolizado por ciclooxigenasas, lipooxigenasas y citocromos P450 mono-oxigenasas, entre otros destinos bioquímicos. Adicionalmente, varios receptores de superficie han sido identificados, como el PLA2R1. En este artículo resumimos la evidencia reciente de la actividad fundamental que las PLA2 juegan en escenarios biológicos y patobiológicos. [García GA, Gaitán AA, García A, Clavijo D, Mejía OR, Cobos C, Casadiego CA. Aspectos biomédicos de las fosfolipasas A2 en la especie humana. MedUNAB 2008;11:14-27].Palabras clave: Fosfolipasa A2 (PLA2), inflamación, malformaciones cerebrales, síndrome metabólico, veneno herpético. | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | spa | spa |
dc.publisher | Universidad Autónoma de Bucaramanga UNAB | |
dc.relation | https://revistas.unab.edu.co/index.php/medunab/article/view/85/77 | |
dc.relation.uri | https://revistas.unab.edu.co/index.php/medunab/article/view/85 | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | |
dc.source | MedUNAB; Vol. 11 Núm. 1 (2008): Priones, Fosfolipasa, Intestino irritable; 14-27 | |
dc.subject | Ciencias biomédicas | |
dc.subject | Ciencias de la vida | |
dc.subject | Innovaciones en salud | |
dc.subject | Investigaciones | |
dc.title | Aspectos biomédicos de las fosfolipasas A2 en la especie humana | |
dc.title.translated | Biomedical aspects of phospholipases A2 in the human species | eng |
dc.publisher.faculty | Facultad Ciencias de la Salud | |
dc.publisher.program | Pregrado Medicina | |
dc.type.driver | info:eu-repo/semantics/article | |
dc.type.local | Artículo | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | |
dc.subject.keywords | Health Sciences | eng |
dc.subject.keywords | Medicine | eng |
dc.subject.keywords | Medical Sciences | eng |
dc.subject.keywords | Biomedical Sciences | eng |
dc.subject.keywords | Life Sciences | eng |
dc.subject.keywords | Innovations in health | eng |
dc.subject.keywords | Research | eng |
dc.subject.keywords | Cerebral malformation | |
dc.subject.keywords | Inflammation | |
dc.subject.keywords | Metabolic syndrome | |
dc.subject.keywords | Phospholipase A2 (PLA2) | |
dc.subject.keywords | Snake venom | |
dc.identifier.instname | instname:Universidad Autónoma de Bucaramanga UNAB | spa |
dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.relation.references | MurakamiM.Hot topics in phospholipaseA2. field. BiolPhami Bull2004;27:1179-82 | |
dc.relation.references | IUMBM. London: lntemational Union of Biochemistry and Molec ula r B iology , 1977 - . D is ponib le e n http://www.chem.qmul.ac.uk/iupac/jcbn/index.html#2. [Fecha deacceso: 16de diciembredel 2007] | |
dc.relation.references | PubMed. Bethesda: National library of Medicine; 1966- Disponible en:http:l/www.ncbi.nlm.nih.gov/PubMedl.[Fecha deacceso 16 dediciembre del2007 | |
dc.relation.references | EMBASE. Amsterdam:Elsevier B.V.; 1974- Disponible en: http:l/www.info.embase.com/embase_com/. [Fecha de acceso: 16dediciembre del2007 | |
dc.relation.references | OMIM. Baltimore: Johns Hopkins University; 1966- Dispomble en:http:llwww.ncbi.nlm.nih.gov/entrez/dispomim; HUGO. Bethesda: National library of Medicine and others (exp.: Celera Genomics and the Sanger Center); 1989- . Disponible en: http://www.hugo-intemational.org/index.html [fecha deacceso 16 dediciembre del2007 | |
dc.relation.references | Dennis EA. Diversity of group types, regulation,and function of phospholipaseA2. JBiolChem 1994; 269:13057-60 | |
dc.relation.references | Schaloske RH, Dennis EA. The phospholipase A2" superfami y and its group numbering system. Biochim BiophysActa 2006; 1761:1246-59 | |
dc.relation.references | Cook JA. Eicosanoids. Crit Care Med 2005; 33(12 Suppl):S488-91 | |
dc.relation.references | Muller CA, Autenrieth IB, PeschelA. lnnate defensas of the intestinal epithelial barrier. Cell Mol Life Sci 2005; 62:1297- 307. | |
dc.relation.references | Keshav S. Paneth cells: leukocy1e-like mediators of innata immunityintheintestina. J Leukoc Biol 2006; 80:500.S | |
dc.relation.references | Zhu J,Massey JB, Mitchell-Leef D. Platelet-activatíng factor acetylhydrolase activity affects sperm molility andserves as a decapacítationfactor. FertilSteril 2006; 85:391-4 | |
dc.relation.references | Wang H, Dey SK. lipid signaling in embryo implantation. ProstaglandinsOther lipidMedial2005;77:84-102 | |
dc.relation.references | Burke JR. Targetíng phospholipase A2. for the treatment of inflammatory skindiseases. Curr Opin lnvestig Drugs 2001; 2:1549-52 | |
dc.relation.references | Stafforini DM, McIntyre TM, Zimmerman GA. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 2003; 40:643-72 | |
dc.relation.references | Spector AA, Fang X, Snyder GD. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 2004; 43:55-90 | |
dc.relation.references | Elbekai RH, El-Kadi AO. Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther 2006; 112:564-87 | |
dc.relation.references | Van Der Stelt M, Di Marzo V. Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem 2004; 271:1827-34 | |
dc.relation.references | Montuschi P, Barnes P, Roberts LJ 2nd. Insights into oxidative stress: the isoprostanes. Curr Med Chem 2007; 14:703-17 | |
dc.relation.references | Milligan G, Stoddart LA, Brown AJ. G protein-coupled receptors for free fatty acids. Cell Signal 2006; 18:1360-5 | |
dc.relation.references | Kostadinova R, Wahli W, Michalik L. PPARs in diseases: control mechanisms of inflammation. Curr Med Chem 2005; 12:2995-3009 | |
dc.contributor.cvlac | García Morán, Grégory Alfonso [0000788503] | |
dc.contributor.cvlac | García Cardona, Ananías [0001665406] | |
dc.contributor.cvlac | Casadiego, Ciro Alfonso [0000302422] | |
dc.contributor.googlescholar | García Cardona, Ananías [2VOuDIMAAAAJ&hl=es&oi=ao] | |
dc.contributor.orcid | García Cardona, Ananías [0000-0002-0202-8950] | |
dc.subject.lemb | Ciencias de la salud | |
dc.subject.lemb | Medicina | |
dc.subject.lemb | Ciencias médicas | |
dc.identifier.repourl | repourl:https://repository.unab.edu.co | |
dc.description.abstractenglish | Phospholipases are a ubiquitous and diverse group of enzymes, described since 1967, that induce changes in membrane composition, activate the inflammatory cascade, and alter cell signaling pathways. Phospholipases A2 (PLA2) are enzymes responsible for the mobilization of fatty acids, including arachidonic acid (AA), from phospholipids. These enzymes are classified into high molecular weight cytosolic PLA2 and low molecular weight secretory PLA2. Arachidonic acid metabolism can follow its metabolism in multiple and interrelated pathways, promoting the generation and release of a wide variety of biologically active substances. Inflammatory cells are capable of releasing arachidonic acid, which can be metabolized by cyclooxygenases, lipoxygenases and cytochrome P450 mono-oxygenases, among other biochemical destinations. Additionally, several surface receptors have been identified, such as PLA2R1. In this article we summarize the recent evidence of the fundamental activity that PLA2 play in biological and pathobiological settings. [García GA, Gaitán AA, García A, Clavijo D, Mejía OR, Cobos C, Casadiego CA. Biomedical aspects of phospholipases A2 in the human species. MedUNAB 2008; 11: 14-27]. Key words: Phospholipase A2 (PLA2), inflammation, brain malformations, metabolic syndrome, herpetic venom. | eng |
dc.subject.proposal | Fosfolipasa A2 (PLA2) | |
dc.subject.proposal | Inflamación | |
dc.subject.proposal | Malformaciones cerebrales | |
dc.subject.proposal | Síndrome metabólico | |
dc.subject.proposal | Veneno herpético | |
dc.type.redcol | http://purl.org/redcol/resource_type/ART | |
dc.rights.creativecommons | Atribución-NoComercial-SinDerivadas 2.5 Colombia | * |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Revista MedUNAB [817]